Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202877 · ClinicalTrials.gov registry record · Phase 1
PKC412 and 5-Azacytidine
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01202877: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01202877 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01202877, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.
Interventions
- DRUG 5-azacytidine
- DRUG PKC412
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01202877
The ClinicalTrials.gov registry entry for NCT01202877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5-azacytidine is the first listed.
NCT01202877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01202877 about?
NCT01202877 is a clinical study titled "PKC412 and 5-Azacytidine". The goal of this clinical research study is to learn if the combination of PKC412 (also called Midostaurin) and 5-azacytidine can help to control refractory or relapsed acute leukemia and MDS. The safety and best dose of the combination of the drugs will also be studied.
What is the current status of trial NCT01202877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2011-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01202877?
The interventions under investigation include: 5-azacytidine (DRUG), PKC412 (DRUG).
Who is sponsoring clinical trial NCT01202877?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.